JP2022033855A5 - - Google Patents

Download PDF

Info

Publication number
JP2022033855A5
JP2022033855A5 JP2021194601A JP2021194601A JP2022033855A5 JP 2022033855 A5 JP2022033855 A5 JP 2022033855A5 JP 2021194601 A JP2021194601 A JP 2021194601A JP 2021194601 A JP2021194601 A JP 2021194601A JP 2022033855 A5 JP2022033855 A5 JP 2022033855A5
Authority
JP
Japan
Prior art keywords
acid sequence
nucleic acid
composition
promoter
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021194601A
Other languages
English (en)
Japanese (ja)
Other versions
JP7315284B2 (ja
JP2022033855A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/033815 external-priority patent/WO2017201527A2/en
Application filed filed Critical
Publication of JP2022033855A publication Critical patent/JP2022033855A/ja
Publication of JP2022033855A5 publication Critical patent/JP2022033855A5/ja
Priority to JP2023044658A priority Critical patent/JP2023078338A/ja
Application granted granted Critical
Publication of JP7315284B2 publication Critical patent/JP7315284B2/ja
Priority to JP2025028446A priority patent/JP2025078652A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021194601A 2016-05-20 2021-11-30 加齢関連疾患及び症状の遺伝子治療法 Active JP7315284B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023044658A JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法
JP2025028446A JP2025078652A (ja) 2016-05-20 2025-02-25 加齢関連疾患及び症状の遺伝子治療法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662339182P 2016-05-20 2016-05-20
US62/339,182 2016-05-20
US201662421665P 2016-11-14 2016-11-14
US62/421,665 2016-11-14
PCT/US2017/033815 WO2017201527A2 (en) 2016-05-20 2017-05-22 Gene therapy methods for age-related diseases and conditions
JP2018560974A JP7632835B2 (ja) 2016-05-20 2017-05-22 加齢関連疾患及び症状の遺伝子治療法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018560974A Division JP7632835B2 (ja) 2016-05-20 2017-05-22 加齢関連疾患及び症状の遺伝子治療法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023044658A Division JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法

Publications (3)

Publication Number Publication Date
JP2022033855A JP2022033855A (ja) 2022-03-02
JP2022033855A5 true JP2022033855A5 (enExample) 2022-09-16
JP7315284B2 JP7315284B2 (ja) 2023-07-26

Family

ID=60326179

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018560974A Active JP7632835B2 (ja) 2016-05-20 2017-05-22 加齢関連疾患及び症状の遺伝子治療法
JP2021194601A Active JP7315284B2 (ja) 2016-05-20 2021-11-30 加齢関連疾患及び症状の遺伝子治療法
JP2023044658A Pending JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法
JP2025028446A Pending JP2025078652A (ja) 2016-05-20 2025-02-25 加齢関連疾患及び症状の遺伝子治療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018560974A Active JP7632835B2 (ja) 2016-05-20 2017-05-22 加齢関連疾患及び症状の遺伝子治療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023044658A Pending JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法
JP2025028446A Pending JP2025078652A (ja) 2016-05-20 2025-02-25 加齢関連疾患及び症状の遺伝子治療法

Country Status (9)

Country Link
US (2) US12281154B2 (enExample)
EP (1) EP3458585A4 (enExample)
JP (4) JP7632835B2 (enExample)
CN (2) CN109844124B (enExample)
AU (2) AU2017268469C1 (enExample)
BR (1) BR112018073861A2 (enExample)
CA (1) CA3025020A1 (enExample)
MX (2) MX2018014256A (enExample)
WO (1) WO2017201527A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018150417A1 (en) * 2017-02-14 2018-08-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Naf-1 derived peptides and uses thereof
KR102616820B1 (ko) * 2017-03-17 2023-12-21 애드베룸 바이오테크놀로지스, 인코포레이티드 향상된 유전자 발현을 위한 조성물 및 방법
MX2019013982A (es) * 2017-05-24 2020-07-22 Univ Autonoma De Barcelona Star Construccion de expresion viral que comprende una secuencia codificadora del factor de crecimiento de fibroblastos 21 (fgf21).
CN111182915A (zh) 2017-08-15 2020-05-19 金德雷德生物科学股份有限公司 兽药用IgG Fc变体
CN111491657A (zh) * 2017-10-20 2020-08-04 哈佛学院院长及董事 用于异源蛋白质生产的人工分泌肽
US11807850B2 (en) 2017-12-06 2023-11-07 Klogenix Llc Compositions and methods for modulating gene expression
SG11202101819QA (en) * 2018-08-30 2021-03-30 Res Inst Nationwide Childrens Hospital Gene therapy for the treatment of galactosemia
MX2021004313A (es) * 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
WO2020106351A1 (en) * 2018-11-21 2020-05-28 Klogenix Llc Increasing gene expression
CN113227126A (zh) * 2018-11-26 2021-08-06 巴塞罗那自治大学 成纤维细胞生长因子21(fgf21)基因治疗
WO2020237186A1 (en) 2019-05-23 2020-11-26 Christiana Care Health Services, Inc. Gene knockout of nrf2 for treatment of cancer
EP3973056A1 (en) 2019-05-23 2022-03-30 Christiana Care Health Services, Inc. Gene knockout of variant nrf2 for treatment of cancer
CN114207135A (zh) 2019-06-11 2022-03-18 夏尔人类遗传性治疗公司 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送
US10653731B1 (en) * 2019-07-15 2020-05-19 Vigene Biosciences Inc. Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
KR102281858B1 (ko) 2019-09-11 2021-07-26 주식회사 쎌바이오텍 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물
CN114555814A (zh) * 2019-09-13 2022-05-27 罗特格斯新泽西州立大学 Aav相容的层粘连蛋白-连接子聚合蛋白
EP4048800A1 (en) 2019-10-23 2022-08-31 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
CN110894508B (zh) * 2019-10-31 2021-08-06 内蒙古大学 一种调控白色脂肪棕色化的基因Adra1a的应用
US20230024183A1 (en) * 2019-12-05 2023-01-26 President And Fellows Of Harvard College Methods for Treating Osteoarthritis
JP7588466B2 (ja) * 2020-01-22 2024-11-22 旭化成メディカル株式会社 パルボウイルスの生産方法
EP4142758A4 (en) * 2020-04-28 2025-02-26 President and Fellows of Harvard College High efficiency gene delivery system
WO2021231730A1 (en) * 2020-05-13 2021-11-18 Lysogene Compositions and methods for treating gm1 gangliosidosis and other disorders
US20230201306A1 (en) * 2020-05-26 2023-06-29 Universitat Autònoma De Barcelona Fibroblast growth factor 21 (FGF21) gene therapy for central nervous system disorders
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途
WO2022115739A2 (en) * 2020-11-30 2022-06-02 Cellular Longevity, Inc. Lnp and liposome compositions for longevity in mammals and methods of using the same
CN116829595A (zh) 2020-12-16 2023-09-29 武田药品工业株式会社 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送
KR102590276B1 (ko) * 2021-01-04 2023-10-16 부산대학교 산학협력단 조직 특이적 발현을 위한 융합 프로모터 및 이의 용도
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
CN113088531B (zh) * 2021-03-25 2023-10-17 四川省药品检验研究院(四川省医疗器械检测中心) 牛源性成分定量分析标准质粒、制备及检测方法及应用
US20240124541A1 (en) * 2021-04-12 2024-04-18 University of Florida Research Foundation, Incorprated Compositions and methods for treating obesity
JP2022169389A (ja) * 2021-04-27 2022-11-09 国立大学法人北海道大学 イヌＴＧＦ－β受容体ＩＩ
US20220401583A1 (en) * 2021-06-16 2022-12-22 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
US20230018934A1 (en) * 2021-07-16 2023-01-19 Genflow Biosciences Srl Method of in vivo administration of the coding sequence of the sirt6 gene via adeno-associated virus
EP4408482A4 (en) * 2021-09-29 2025-11-12 Sirt6 Ltd METHOD OF TREATING A DISEASE
CN114921480A (zh) * 2022-06-09 2022-08-19 国科宁波生命与健康产业研究院 一种骨细胞Terc基因敲除小鼠模型的构建方法
WO2024064796A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for arrhythmogenic cardiomyopathy
WO2024064785A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for familial partial lipodystrophy
KR20250069649A (ko) * 2022-09-21 2025-05-19 리쥬버네이트 바이오 인크 승모판 질환 치료를 위한 유전자 치료법 방법
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物
WO2025109173A1 (en) 2023-11-22 2025-05-30 Advantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight
EP4566618A1 (en) * 2023-12-06 2025-06-11 ADvantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
PT975771E (pt) 1997-04-18 2007-10-01 Biogen Idec Inc Proteínas de fusão da região constante da imunoglobulina/receptor do ftc-beta do tipoii
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US7419829B2 (en) * 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
WO2003059396A1 (en) * 2002-01-11 2003-07-24 Sergei Zolotukhin Adiponectin gene therapy
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
EP1812450A2 (en) * 2004-11-10 2007-08-01 Eli Lilly And Company Tgf-beta inhibitors
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
PL1874818T3 (pl) * 2005-04-22 2011-09-30 Lilly Co Eli Przeciwciała swoiste wobec TGF-beta 1
DE102005061840A1 (de) * 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
US20070292922A1 (en) 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
JP5421109B2 (ja) * 2006-09-13 2014-02-19 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 低カルボキシル化／非カルボキシル化オステオカルシンはベータ細胞増殖、インスリン分泌、インスリン感受性、耐糖能を増加させ、体脂肪量を減少させる
EP2171062A1 (en) * 2007-06-15 2010-04-07 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
US8236557B2 (en) * 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
JP6066732B2 (ja) * 2010-03-05 2017-01-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
AR083445A1 (es) * 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
PL2455104T3 (pl) * 2010-11-19 2013-12-31 Univ Freiburg Bio-funkcjonalizowane reagujące na bodziec rozpuszczalne hydrożele PEG
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US20140213512A1 (en) * 2011-08-31 2014-07-31 Amgen Inc. Method of Treating or Ameliorating Type 1 Diabetes Using FGF21
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
CN103203027A (zh) * 2011-11-03 2013-07-17 阳明大学 用于治疗和预防老化相关症状的方法和组分
WO2013111081A1 (en) 2012-01-24 2013-08-01 Bar-Ilan University Treatment of disease by modulation of sirt6
CN103665166A (zh) * 2012-09-03 2014-03-26 福又达生物科技股份有限公司 犬融合干扰素
WO2014152993A1 (en) 2013-03-14 2014-09-25 The Board Of Regents Of The University Of Oklahoma Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions
EP3129043A4 (en) * 2014-04-08 2017-11-15 University of Southern California Polypeptide compositions with type vii collagen fibronectin type iii- like repeats and treatment methods for wound closure and healing
KR20150135148A (ko) * 2014-05-23 2015-12-02 주식회사 제넥신 Pd-l1 융합 단백질 및 이의 용도
SG11201702824UA (en) * 2014-10-24 2017-05-30 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
EP3334750B1 (en) * 2015-08-11 2022-10-05 Anie Philip Peptidic tgf-beta antagonists

Similar Documents

Publication Publication Date Title
JP2022033855A5 (enExample)
JP2025078652A5 (enExample)
IL299325B2 (en) Acid-alpha glucosidase variants and uses thereof
JP2020114235A5 (enExample)
JP2022190081A5 (enExample)
JP2019519221A5 (enExample)
IL292264B1 (en) Aav transfer cassette
JP2020520643A5 (enExample)
JP2018522529A5 (enExample)
JP2008506389A (ja) Ａａｖベクター組成物および免疫グロブリンの発現の増強のための方法ならびにその使用方法
JPWO2020106916A5 (enExample)
JP2018526003A (ja) イヌの癌を治療するためのキメラａａｖ−抗ｖｅｇｆ
JP2003505033A5 (enExample)
JP2024099770A5 (enExample)
JPWO2020033473A5 (enExample)
JP2023065516A5 (enExample)
JPWO2021067448A5 (enExample)
JPWO2019161059A5 (enExample)
JPWO2020214609A5 (enExample)
JPWO2019165050A5 (enExample)
JPWO2020243651A5 (enExample)
JPWO2020168222A5 (enExample)
JPWO2020159970A5 (enExample)
JPWO2020186207A5 (enExample)
JPWO2021113642A5 (enExample)